Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 9/20 | 0.44 |
| ▸ | PGR | P06401 | 11/20 | 0.44 |
| ▸ | AR | P10275 | 8/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | ESR1 | P03372 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SHBG | P04278 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5502772 | 1.00 | NR3C1 (0.44) | NR3C1PGRARCYP3A4LMNA | |
| SCHEMBL7510425 | 1.00 | NR3C1 (0.44) | NR3C1PGRARCYP3A4LMNA | |
| SCHEMBL5502771 | 1.00 | NR3C1 (0.44) | NR3C1PGRARCYP3A4LMNA | |
| SCHEMBL5501467 | 0.90 | NR3C1 (0.44) | NR3C1PGRARCYP3A4LMNA | |
| SCHEMBL8767959 | 0.88 | NR3C1 (0.46) | NR3C1PGRARCYP3A4LMNA | |
| SCHEMBL8768908 | 0.88 | NR3C1 (0.46) | NR3C1PGRARCYP3A4LMNA | |
| SCHEMBL5498047 | 0.85 | NR3C1 (0.44) | NR3C1PGRARCYP3A4LMNA | |
| SCHEMBL5499361 | 0.85 | NR3C1 (0.41) | NR3C1PGRARCYP3A4LMNA | |
| SCHEMBL8768225 | 0.85 | PGR (0.47) | NR3C1PGRARCYP3A4LMNA | |
| SCHEMBL8768220 | 0.85 | PGR (0.47) | NR3C1PGRARCYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020143000-A1 | Use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143000-A1 | Use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment | FSHR, GNRHR, NR5A1 | NR3C1 61/4885PGR 4/4885AR 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.